Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report

Jian Wang, Bingyue Liu, Qinhong Zheng, Ruoshui Xiao, Jianxin Chen · 2024

Read Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report by Jian Wang, Bingyue Liu, Qinhong Zheng, Ruoshui Xiao, Jianxin Chen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11668661.txt.

Description

Jian Wang and co-authors report a 2024 case where a lung cancer gained a new drug target after resisting immunotherapy. The tumor had no driver changes at first and was treated with an immune checkpoint drug. When resistance developed, testing found a fresh fusion joining the CD74 gene to ROS1, a growth switch gene seen in only a small share of lung cancers. No acquired case like this had been reported before.

The patient then received a targeted drug against that fusion and achieved a partial response. The authors suggest the fusion carrying cells were a minority that grew to dominate once treatment removed their rivals. Their lesson is practical: retest tumor genetics after long immunotherapy. New targets may appear, and finding them can reopen treatment options.

Catalog record

CREATORJian Wang, Bingyue Liu, Qinhong Zheng, Ruoshui Xiao, Jianxin Chen
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11668661

Browse the full library · About the Tower of Babel